Abstract: Programmed death ligand-1 (PD-L1) immunohistochemistry is used to guide treatment decisions regarding the use of checkpoint immunotherapy in the management of urothelial carcinoma of the bladder and hypopharyngeal (HP) squamous cell carcinoma. With increasing PD-L1 testing options, a need has arisen to assess the analytical comparability of diagnostic assays in order to develop a more sustainable testing strategy. Using tissue microarrays, PD-L1 expression in tumor cells (TCs) and immune cells (ICs) was manually scored in 197 cases and 27 cases of bladder and HP cancer, respectively. Three commercial kits (Ventana SP263, Ventana SP142, Dako 22C3) and 1 platformindependent test (Cell Signalling Technologies E1L3N) were utilized. Across the 3 commercially available clones, 14% and 74% of urothelial carcinomas were positive and negative, respectively, whereas 7% and 78% of HP carcinomas were positive and negative, respectively. Twelve percent of bladder and 15% HP cases showed discrepant PD-L1 classification results. Regardless of the scoring algorithm used, E1L3N provided comparable PD-L1 staining results. Fleiss' kappa and intraclass correlation coefficient (ICC) analyses demonstrated substantial agreement among all antibody clones (k = 0.639 to 0.791) and excellent reliability among SP263, 22C3, and E1L3N antibodies (ICC, 0.929 to 0.949) in TC staining. Compared with the other 3 clones, SP142 TC staining was lower with only moderate correlation (ICC, 0.500 to 0.619). Generally, the reliability of immune cell staining was lower compared with TC staining (ICC, 0.519 to 0.866). Our results demonstrate good analytic comparability of all 4 antibodies. The results are encouraging and support growing optimism in the pathology and oncology communities concerning strategies in PD-L1 assay use.
Abstract: Programmed death ligand-1 (PD-L1) immunohistochemistry is used to guide treatment decisions regarding the use of checkpoint immunotherapy in the management of urothelial carcinoma of the bladder and hypopharyngeal (HP) squamous cell carcinoma. With increasing PD-L1 testing options, a need has arisen to assess the analytical comparability of diagnostic assays in order to develop a more sustainable testing strategy. Using tissue microarrays, PD-L1 expression in tumor cells (TCs) and immune cells (ICs) was manually scored in 197 cases and 27 cases of bladder and HP cancer, respectively. Three commercial kits (Ventana SP263, Ventana SP142, Dako 22C3) and 1 platformindependent test (Cell Signalling Technologies E1L3N) were utilized. Across the 3 commercially available clones, 14% and 74% of urothelial carcinomas were positive and negative, respectively, whereas 7% and 78% of HP carcinomas were positive and negative, respectively. Twelve percent of bladder and 15% HP cases showed discrepant PD-L1 classification results. Regardless of the scoring algorithm used, E1L3N provided comparable PD-L1 staining results. Fleiss' kappa and intraclass correlation coefficient (ICC) analyses demonstrated substantial agreement among all antibody clones (k = 0.639 to 0.791) and excellent reliability among SP263, 22C3, and E1L3N antibodies (ICC, 0.929 to 0.949) in TC staining. Compared with the other 3 clones, SP142 TC staining was lower with only moderate correlation (ICC, 0.500 to 0.619). Generally, the reliability of immune cell staining was lower compared with TC staining (ICC, 0.519 to 0.866). Our results demonstrate good analytic comparability of all 4 antibodies. The results are encouraging and support growing optimism in the pathology and oncology communities concerning strategies in PD-L1 assay use. T he use of checkpoint inhibitors in the management of various malignancies has become increasingly prevalent following successful early clinical trials. 1 The programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) checkpoint has emerged as a key checkpoint that can be manipulated using inhibitory monoclonal antibodies. In this context, the expression profile of PD-L1, is typically evaluated to identify patients most likely to derive clinically meaningful benefit from such inhibitors. 2, 3 PD-1 is usually expressed on adaptive immune cells (ICs) as well as natural killer cells while PD-L1, in addition to being expressed by lymphocytes, is expressed by different antigen-presenting cells and endothelial cells. 1 Normal physiological interactions between this receptor-ligand pair inhibit the immune response, and thus these molecules play an important role in the prevention of autoimmunity through the promotion of self-tolerance. 4, 5 Remarkably, it has been shown that the PD-1/PD-L1 pathway is used by tumor cells (TCs) to evade recognition by the host immune system, as PD-L1 can also be expressed by a multitude of tumors. 6 Because of this, the PD-1/PD-L1 pathway has become the target of intense oncologic and pathologic research, as it has been shown that blockade of PD-1 and/or PD-L1 has positive therapeutic benefit. 7, 8 Certain checkpoint inhibitors are already available for use in the treatment of both urothelial carcinoma (UC) [9] [10] [11] [12] [13] [14] and squamous cell carcinoma (SCC) of the head and neck [15] [16] [17] [18] and others are being evaluated in clinical trials. In order to determine patient candidacy for treatment with these drugs, immunohistochemical testing is used to evaluate expression of PD-L1 in tumor samples. Multiple assays are available for diagnostic use, each with its own primary antibody, specific assay performance conditions, and scoring methods. Within each assay, the cut-off levels required for positivity will vary depending on tumor type. Evaluation of PD-L1 expression in tumor tissue is complicated by many factors. 6 With multiple assays available, each linked with a specific therapeutic agent, identification of patients who may benefit from immune checkpoint inhibition can be challenging. Given limited tissue and resource availability coupled with platformspecific assay requirements, performing multiple assays for each patient is ultimately impractical. As such, it is imperative to understand the potential interchangeability of various assays, given the critical clinical implications.
This issue of assay comparison and interchangeability has been investigated in the context of several organs, mainly non-small cell carcinoma of the lung [19] [20] [21] However, data for both UC and hypopharyngeal (HP) SCC are lacking.
With this in mind, we sought to assess and compare the analytic performance of 3 commercially available in vitro diagnostic (IVD) PD-L1 expression assays (Ventana SP263, Ventana SP142, and Dako 22C3) in UC of the bladder and HP-SCC. In addition, we assessed the performance of a platform-independent laboratory developed test, Cell Signalling Technologies E1L3N antibody. 
MATERIALS AND METHODS

Case Selection
Tissue Microarray Construction
Triplicate 1-mm core tissue microarrays (TMAs) were constructed using a TMA instrument (Beecher Instruments, Silver Springs, MD) as previously described. 22 The cores were taken as follows: 1 punch from tumor front, 1 from superficial tumor, and 1 from mid portion of tumor to control for temporal heterogeneity. Sections from the TMA blocks were stained with hematoxylin and eosin to confirm the adequacy of tumor sampling and to facilitate orientation during the interpretation of the anti-PD-L1 staining.
Immunohistochemistry
Serial unstained slides (4 μm) were prepared from each block for subsequent immunohistochemistry with the following PD-L1 antibody clones: SP142 and SP263 (Ventana Medical Systems, Arizona), 22C3 (Agilent Technologies, California), and E1L3N (Cell Signaling Technologies, Massachusetts). Staining for anti-PD-L1 rabbit mAb clones SP142, SP263, and E1L3N was performed on the Ventana Benchmark Ultra automated staining platform according to the manufacturer's protocol (with the Optiview DAB IHC detection kit for all the clones, followed by the Optiview amplification kit for SP142 only; for mouse mAb clone 22C3, the Dako EnVision FLEX system on a Dako Autostainer Link 48 system was used according to the manufacturer's instructions ( Fig. 1 ).
Scoring TC and IC Staining
The UC (n = 197) and HP-SCC cases (n = 27) were read and interpreted by fellowship-trained Genitourinary (M.R.D.) and Head and Neck (B.X.) pathologists, respectively. TC staining was defined as either partial or complete membranous staining of TCs of any intensity. IC (lymphocytes and macrophages) staining was either cytoplasmic or membranous of any intensity. The identification of TC and IC was based on morphologic features alone with assistance of hematoxylin and eosin slides. Both TC and IC staining was assessed as either presence or absence with the estimated percentage of positive TC and positive IC recorded for each TMA core. For both the UC and HP-SCC cases, there was variability in PD-L1 expression from core to core. To counter this, the results were averaged across the triplicate cores to give 1 estimate of percentage TC and percentage IC for each case. Each of the 4 assays was assessed with a wash out period of several days between each round of scoring.
Application of Clinical Algorithms
For each of the 3 commercially available IVD assays (SP142, SP263, and 22C3), the site-specific manufacturer's algorithm was applied to each case (Supplementary Table 1, Supplemental Digital Content 1, http://links.lww. com/PAS/A627). This was used with the recommended cut-off to designate cases as "positive" or "negative" as would be required for clinical use of the associated immune checkpoint inhibitor. The scoring was performed by the same pathologists as the TC/IC scoring.
For UC of the bladder, the SP263 staining was considered a positive result if ≥ 25% tumor or ICs were staining. SP142-stained sections were deemed positive when the positive ICs represented ≥ 5% of the TC area. The 22C3 staining was recorded as positive when the combined proportion score was ≥ 10%. The combined proportion score was calculated by combining the positive TC and IC staining and expressing it relative to the total TCs.
For HP-SCC, the SP263 staining was considered a positive result if ≥ 25% TCs were stained. SP142-stained sections were deemed positive when ≥ 50% TCs or ≥ 10% ICs showed immunopositivity. The 22C3 staining was recorded as positive when ≥ 50% TC showed partial or complete membranous staining.
The average TC and IC percentage scores of E1L3N anti-PD-L1 stained sections were then assessed applying one of the algorithms for SP142, SP263, and 22C3 to allow comparison of E1L3N antibody clone with the other 3 clones.
Statistics
All statistical analyses were performed using the SPSS software 24.0 (IBM Corporation, New York, NY). The agreement of the overall positivity and negativity determined using individual algorithms for PD-L1 clones 22C3, SP142, and SP263 was assessed using Fleiss' kappa statistics. Kappa analysis was also applied to compare the performance of E1L3N clone with the other 3 clones by means of applying appropriate algorithms as described in Supplementary 
RESULTS
Characteristics of the Study Cohort
The clinical and pathologic features of the study cohort are presented in Table 1 . In brief, there were 197 UC patients including 143 males and 54 females. The median age at presentation was 71 years (range, 33 to 93 y). Seventy-four percent of UCs were the usual type, whereas the remaining showed divergent differentiation. The majority of the patients had advanced primary tumors at the time of resection, including 55% with pT3 and 28% with pT4 disease. Lymph node metastases were found in 79 (40%) of cases.
Among the 27 patients with HP-SCC, the median age as 64 years (range, 49 to 79 y). There was a male predominance with a male:female ratio of 3:1. Twenty (74%) primary tumors were moderately differentiated, whereas the rest was poorly differentiated. Nineteen (70%) patients had nodal metastases at the time of primary resection.
PD-L1 Immunopositivity in UC and HP-SCC: A Comparison of Performance Among Antibody Clones With Established Clinical Algorithms
The performance of 22C3, SP263, and SP142 clones is illustrated in Figure 2 . Among the 197 UCs studied, 27 (14%) tumors were considered as positive, whereas 137 (74%) were negative across all 3 antibody clones. The remaining 23 tumors (12%) showed inconsistent results. In the 27 HP-SCCs tested, 2 (7%) were universally positive; 21 (78%) were consistently negative, whereas the remaining 4 (15%) exhibited discrepant results. The number and percentage of UC deemed PD-L1 positive were 41 (21%) using SP263 clone, 36 (18%) using SP142 clone, and 40 (20%) using 22C3 Table 1 . Orange: PD-L1-negative tumors.
clone. The number and percentage of HP-SCC that were positive for PD-L1 were 5 (19%) using SP263 clone, 3 (11%) using SP142 clone, and 3 (11%) using 22C3 clone. Figure 3 provides comparison between the E1L3N clone and each of the other clones using the same algorithm to determine PD-L1 positivity and negativity. Regardless of the algorithm used, E1L3N provided comparable results of PD-L1 immunopositivity: in UC, 20%, 17%, and 28% of cases were positive using SP263, SP142, and 22C3 algorithms, respectively. For HP-SCC, 15%, 15%, and 7% of cases were positive using SP263, SP142, and 22C3 algorithms, respectively. Only a minority of cases showed discrepant results (positive with 1 clone but negative with the other) among E1L3N and one of the other antibody clones: in UC, this was 8% (SP263), 11% (SP142), and 10% (22C3); in HP-SCC, 4% of cases were discrepant when any of the 3 clones were compared.
Pairwise Comparisons of PD-L1 Antibody Clones
The results of Fleiss' kappa analyses are shown in Table 2 . There was substantial agreement between any of the 2 antibody clones compared (P < 0.001). The kappa value ranged from 0.639 to 0.791.
The actual percentage of TCs and ICs were compared using ICC analysis, and the results are illustrated in Table 2 and Figure 4 (left panel). Overall, a near-perfect correlation of the actual TC scores was achieved (1) between SP263 and 22C3; (2) between SP263 and E1L3N; and (3) between 22C3 and E1L3N. In contrast, the actual TC percentage rated using SP142 antibody appeared to be lower than the other 3 antibodies.
Generally, the reliability of IC scoring appeared to be lower compared with the reliability of TC score. There was good reliability of 22C3 and E1L3N IC scoring (ICC = 0.866, 95% CI = 0.826-0.897), and moderate reliability in any other pairwise comparisons including (1) Figure 4 (right panel). The IC score appeared to be highest in SP142, followed by E1L3N and 22C3, and lowest in SP263.
DISCUSSION
PD-L1 inhibitors are being used to treat many different malignancies including SCC of the head and neck and UC of the bladder. As these therapeutic options become increasingly used, the demands for pathologic testing will also increase. Currently, testing for PD-L1 immunohistochemical expression is governed by little standardization, leading to multiple assays which utilize different clones, staining platforms, and scoring algorithms. 23 From a practical point of view, a need has arisen to evaluate the concordance between assays, in order to develop a more sustainable and logistically sound testing strategy. Because of this, we endeavored to compare the diagnostic performance of 3 commonly used commercially available in vitro assays (Ventana SP263 and SP142, and Dako 22C3). In addition, we sought to assess how a laboratory developed test (Cell Signalling Technologies E1L3N) would compare when the same parameters for each in vitro assay were applied. Our results have demonstrated several important points including (1) a high level of concordant PD-L1 scoring results among the 3 commercially available assays, (2) comparable PD-L1 positivity regardless of algorithm when E1L3N antibody was used, (3) substantial agreement of PD-L1 positivity interpretation between any of the 2 utilized antibody clones by Fleiss' kappa analysis, (4) excellent reliability as determined by intraclass correlation efficient analysis for TC staining for 3 clones, and (5) an overall lower reliability for IC staining. It is worth noting that TC staining is not a component of the UC SP142 algorithm even though TC staining is seen in some cases. Therefore, it is not surprising that TC staining in UC is less than that with the other 3 antibodies.
We have shown here that there are diagnostic similarities between the 4 tested PD-L1 systems. The low level of discrepant results between SP263, SP142, and 22C3 antibodies that was observed in our study is reassuring, and is not dissimilar to what has been recently reported in studies of bladder cancer 24 and lung cancer 25, 26 (different combinations of antibodies used). Interestingly, the number of discrepant results for both bladder and HP cases in our study is significantly lower than what was reported in the Blueprint study on non-small cell carcinoma of the lung 19 : 37% versus 12% and 15% for bladder and HP cases, respectively. Multiple factors, including specimen type and antibody clones compared may attribute to the different discrepancy rate between the 2 studies. While our study utilized TMAs, the Blueprint study included whole sections from surgical resections and biopsies, which may contribute to greater intratumor heterogeneity and additional interpretation subjectivity. The present study included 3 commercially available antibodies while the Blueprint study also involved PD-L1 28-8 clone, which might add additional interpretation difference between antibody clones.
The E1L3N antibody clone which is staining platform independent, showed remarkably concordant performance compared with the IVD clones. These results are in keeping with another study in UC. 24 Such comparative studies in HP carcinoma have not been published to date. Not unexpectedly, the SP142 antibody was found to stain less TCs compared with the other antibodies in both UC and SCC groups, a finding recently reported in other organ systems. 19, 21, 27 The scoring algorithm for SP142 in the evaluation of both UC of the bladder and HP-SCC incorporates IC staining. While SP142 showed a similar overall diagnostic performance, pairwise comparisons only demonstrated moderate reliability in TC and IC staining when compared with the other 3 clones. This is explained by the fact that SP142 tends to stain more IC, and less TC. It could be argued that the same challenges that are experienced with IC staining should apply to SP263, as IC staining is incorporated into the scoring algorithm of SP263 specifically in UC of the bladder. This is not the case for 2 reasons: first, SP263 scoring in UC of the bladder also incorporates TC staining (and TC staining for this clone showed excellent reliability compared with 22C3 and E1L3N), and second, it is has been noted that SP142 IC staining may exhibit unusual staining patterns or may be low level/frequency, again making interpretation more difficult. 28 It has been noted that PD-L1 staining suffers from intratumoral heterogeneity in different tumor types. [29] [30] [31] This finding suggests that that tumor sampling based only on small biopsy material may wrongly classify patients based on PD-L1 status. A study looking at non-small cell lung carcinoma biopsy and subsequent surgical resection specimens demonstrated an eventual difference in PD-L1 expression. 32 Additional studies are needed to evaluate whether such difference may be also applied to bladder and head and neck cancers. Prospective studies on biopsy and subsequent surgical materials from bladder and head and neck cancers are needed. However, in a study evaluating PD-L1 staining heterogeneity, no significant intrablock or intracase heterogeneity was noted in cases of UC and SCC of the head and neck. 31 Antibody evaluation and comparison by TMA has been previously done in the evaluation of primary and metastatic bladder cancer samples with different PD-L1 antibody clones. 24 In this study, we have minimized the impact of intratumoral heterogeneity by assessing tumors using triplicate cores from different tumor areas, and the staining results have been averaged. In addition, heterogeneity was also mitigated by evaluating staining by the different clones in consecutive serial sections.
A limitation of our study was the relatively small number of HP-SCC cases, which was due to the tumor's relative rarity 33 and the fact that, like other malignancies of the aerodigestive tract, these lesions are typically treated with a multimodal approach 34 and may not be surgically resected depending on the extent of disease. Another potential limitation of the present study is that the evaluation of PD-L1 was performed on TMAs, as it is known that PD-L1 immunoexpression may be heterogenous. 35, 36 Hence, the PD-L1 score obtained using TMAs and small biopsies may not always be consistent with the PD-L1 immunostain based on whole slides from surgical resection. Indeed, variability of PD-L1 scores was observed among cores from the same tumor across different antibody clones in our study (data not shown), which reflected the intrinsic staining heterogenicity of PD-L1 within bladder and head and neck carcinomas. In an attempt to address this issue, multiple cores were sampled for each tumor and the PD-L1 score was averaged for each case.
Similar to phase 1 of the Blueprint comparison project, 19 our study utilized a small number of expert pathologists to evaluate the cases. As was acknowledged in the similar nonsmall cell lung cancer study, the generalizability of the results to nonexperts is unknown. Studies evaluating the generalizability as well as reproducibility of assay interchangeability are needed in the future. Importantly, our study does not address nor compare the outcome predictive value of this interchangeable assay strategy. This type of analysis will be critical in the future, in order to validate these promising alternative testing approaches.
In conclusion, the performance of the 4 compared PD-L1 antibody assays demonstrated in our study is encouraging. The results presented here support previously reported data from other malignancies, and complement ongoing comparative studies. From a practical point of view, several issues related to PD-L1 testing could be eliminated through the use of a single harmonized assay delivery and interpretation system. In addition, the potential for cost savings 37 and a more stream-lined and efficient testing process cannot be ignored in the era of personalized medicine.
